UPEXI, INC.
UPXINasdaq
$0.80
↓ -4.3%Jul 17 close · end-of-day
Price
1Y↓ -88.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$52.7M
Enterprise Value
$110.0M
P/E
—
P/S
2.0
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-41.3%
Dividend Yield
—
Revenue (TTM)
$26.1M
Net Income (TTM)
-$228.4M
Free Cash Flow (TTM)
-$21.8M
Gross Margin
87.0%
Operating Margin
-839.8%
Net Margin
-874.0%
ROE
440.0%
ROIC
-3224.6%
Debt / Equity
-1.1
Net Cash
-$57.3M
Return 1Y
-88.9%
Company profile
Upexi, Inc. engages in the development, manufacture, and distribution of consumer products. It offers nail grinder and healthy all-natural pet supplements under the LuckyTail brand; energy solutions under the PRAX brand; functional mushrooms under the Cure Mushrooms brand; cannabinoid under the Moonwlkr brand; and gummies and other products under the Gumi Labs brand name. The company sells its products through direct-to-consumer network, wholesale partnerships, and third-party platform. It also focuses on cryptocurrency industry and management of cash assets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. Upexi, Inc. was incorporated in 2018 and is headquartered in Tampa, Florida.
- CEO
- Allan Marshall
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 59
- Headquarters
- Florida
- Website
- www.upexi.com
Earnings
UPXI Q3 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$4.6M↑ +44.2%
Diluted EPS-$1.67↓ -41.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $24.1M | $23.1M | $36.4M | $26.0M | $15.8M |
| Gross profit | $11.9M | $14.9M | $21.0M | $12.8M | $10.9M |
| Operating income | $1.4M | -$6.5M | -$12.3M | -$22.5M | -$12.5M |
| Net income | $3.0M | -$2.0M | -$17.5M | -$23.7M | -$13.7M |
| Diluted EPS | $0.21 | -$0.43 | -$18.94 | -$23.03 | -$1.73 |
| Operating cash flow | $2.9M | -$180,831.00 | $202,677.00 | -$101,376.00 | -$8.4M |
| Free cash flow | $1.5M | -$5.6M | -$734,887.00 | -$1.0M | -$8.8M |
| Gross margin | 49.4% | 64.5% | 57.7% | 49.3% | 68.7% |
| Operating margin | 5.9% | -28.1% | -33.7% | -86.4% | -79.1% |
| Net margin | 12.4% | -8.9% | -48.0% | -91.0% | -86.5% |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0M | $4.4M | $4.0M | $3.2M | $4.3M | $9.2M | $8.1M | $4.6M |
| Gross profit | $1.6M | $2.9M | $3.0M | $1.6M | $3.4M | $8.3M | $6.7M | $4.4M |
| Operating income | -$13.4M | -$1.3M | -$1.1M | -$3.6M | -$6.5M | $69.2M | -$175.4M | -$106.8M |
| Net income | -$15.7M | -$1.6M | -$1.3M | -$3.8M | -$6.9M | $66.7M | -$178.9M | -$109.3M |
| Diluted EPS | -$15.66 | $1.55 | -$1.24 | -$2.87 | $0.83 | $0.76 | — | -$1.67 |
| Operating cash flow | $2.7M | -$2.0M | -$1.4M | -$778,710.00 | -$4.3M | -$9.8M | -$2.7M | -$4.8M |
| Free cash flow | $2.5M | -$2.1M | -$1.4M | -$809,299.00 | -$4.5M | -$9.8M | -$2.7M | -$4.8M |
| Gross margin | 31.0% | 67.3% | 74.3% | 49.3% | 79.4% | 89.6% | 83.3% | 95.5% |
| Operating margin | -265.2% | -30.6% | -26.8% | -113.5% | -151.7% | 748.5% | -2177.9% | -2343.3% |
| Net margin | -312.4% | -37.3% | -32.5% | -121.2% | -161.5% | 722.4% | -2222.1% | -2399.4% |
Company news
May 13, 2026
Mar 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.